Vitaspero Inc. (Latin for Life and Hope) was created to bring a new technology of immunotherapy to those suffering from hepatitis-C and cancer. Correcting the malfunctioning immune system is the basis of this immunotherapy treatment.

Unlike conventional methods of treating cancer with toxic chemical agents and radiation, immunotherapy is not toxic; it does not jeopardize other organs, and, significantly, does not destroy the immune cells that are necessary for fighting the disease in the first place.

Vitaspero's efforts are primarily centered on the immunotherapeutic vaccines - the autologous cells vaccine on the basis of dendritic cells and T-lymphocytes - based on the ideas and technologies of a research scientist in St.Petersburg, Russia.

Adding a vaccine developed for glyoma to conventional therapy (chemotherapy and radiation) showed a 50% increase in survival rate (12 vs.18 months). At 36 months survival rates were 20% compared to 0 for conventional therapy. A similar technology was developed in the US by Dendreon obtaining FDA approval in April 2010. Their median survival rates improved by 4 months. Noteworthy is that at 12 months conventional therapy shows zero survival rate. Adding the vaccine shows 20% survival after 36 months.

The same technology has shown to be useful in Hepatocellularcarcinoma/Hepatitis C. A Russian patent application was filed in May 2010. About 4 million in the US and 9 million in Europe suffer from this disease, and about half of them will not respond to current treatment.

1. Considering that Vitaspero's efforts are primarily centered on immunotherapeutic vaccines - the autologous cells vaccine on the basis of dendritic cells and T-lymphocytes – what is the best IP strategy for commercializing our technology?

2. Vitaspero is interested in identifying strategic partnerships. Which companies should we approach and how can we recruit a partner to help advance the technology and still keep open the possibility of future acquisition?

3. Because the Russian regulatory equivalent of the FDA has little or no experience with autologous vaccines and many US physicians are already conducting clinical trials using cancer vaccines, what is Vitaspero's best regulatory strategy for advancing the technology here in the US, and who are the best candidates for conducting the trials?

6:30 - Cocktails & Dinner (Cash bar and special 2-entree buffet menu)

8:00 - Anna Gutkina, President of Vitaspero, will deliver the Company's "Elevator" Pitch to the Group

8:20 - A Panel will address 3 Major Issues for the Company

9:00 - Open discussion: members and guests

<Top of the page>

Available Media Please note: All information obtained here is the property of those presenting and should not be copied or duplicated without written consent. Slides None available at this time Audio None available at this time Video None available at this time Webcast Vitaspero Webcast - 02/15/11

List of Attendees

Questions or Coments?

Contact: Peter van der Kam,

peter@rxpcci.com | (610) 296-8086

Good Company! Good Drink! Good Food! Good Program! Good Fun!

Site Navigation

HOME  |  ABOUT PCCI  |   DIRECTIONS  |   BRIDGEWATER DIRECTIONS  |   JOIN US  |   BOARD MEMBERS  |   AFFILIATES  |  NEXT MEETING  |  ARCHIVES

PROFILES CALENDAR OF EVENTS  |  BRIDGEWATER CHAPTER  |  FEEDBACK / COMMENTS  |   CONTACT US

Pharmaceutical Consulting Consortium International, Inc.,

info@rxpcci.com or (610) 296-8086

Meetings Held at Embassy Suites - Valley Forge

888 Chesterbrook Blvd, Chesterbrook, Pennsylvania 19087

All content on this website is copyrighted and should not be reproduced without the consent of PCCI.

© Copyright 2016-2018